Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Moderna (MRNA) Initiates Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins

July 27, 2020 6:52 AM EDT

Phase 3 study being conducted in collaboration with NIH and BARDA

Expected to enroll 30,000 participants in the U.S.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3 study, called the COVE (Coronavirus Efficacy) study, is being conducted in collaboration with the... More